Hepatitis C Infection clinical trials
23 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
- Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Trial of Ixazomib for Kaposi Sarcoma
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
- Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
- The Hepatitis C Transplant Collaborative
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
- Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Hepatitis C Infection” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.